Browsing Tag
Lexicon Pharmaceuticals
3 posts
AHA 2025 spotlight: sotagliflozin data spark debate on benefits in HFpEF patients without diabetes
Find out how sotagliflozin’s debated HFpEF results at AHA 2025 could change heart-failure therapy beyond diabetes.
RELIEF-DPN-1 clinical trial : Lexicon begins patient dosing with LX9211
RELIEF-DPN-1 clinical trial : Lexicon Pharmaceuticals has started patient dosing in a phase 2 trial of LX9211 for…
FDA approves Lexicon Pharmaceuticals’ Xermelo for carcinoid syndrome diarrhea
Lexicon Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its oral drug Xermelo…